Federal Cannabis Rescheduling: DEA Process, Timeline & Impact

Executive Summary

Federal cannabis rescheduling—the process of moving marijuana from Schedule I to a lower tier under the Controlled Substances Act—represents the most significant federal drug policy shift in over five decades. In May 2026, President Trump completed the rescheduling of cannabis to Schedule III, a move initiated during the Biden administration in 2022. This administrative action, conducted through the Drug Enforcement Administration and Department of Health and Human Services, does not legalize cannabis federally but reclassifies it alongside substances like ketamine and anabolic steroids. The change eliminates the punitive 280E tax code provision that prevented cannabis businesses from deducting ordinary expenses, potentially saving the industry billions annually. However, advocacy groups including the National Organization for the Reform of Marijuana Laws and the Drug Policy Alliance immediately called on Congress to pursue full descheduling and legalization, arguing that Schedule III status leaves fundamental prohibition intact while creating new regulatory complications. The rescheduling affects approximately 15,000 licensed cannabis businesses across 38 states with medical programs and 24 states with adult-use markets, representing a combined industry valued at $33 billion in 2025.

Why Federal Rescheduling Matters

The reclassification of cannabis from Schedule I to Schedule III affects every stakeholder in the $33 billion U.S. cannabis ecosystem—from cultivators and dispensaries to patients, investors, and state regulators. For cannabis operators, the immediate impact centers on Internal Revenue Code Section 280E, which since 1982 has prohibited businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. Industry analysts estimate this tax burden costs cannabis companies 40-70% effective tax rates compared to 21-30% for comparable non-cannabis businesses. Schedule III status eliminates this penalty, potentially freeing $1.5-3 billion annually in capital that operators can redirect toward expansion, debt reduction, or price competition. For medical patients, rescheduling validates decades of advocacy asserting cannabis has accepted medical use. Approximately 6.7 million registered medical cannabis patients across 38 states gain federal acknowledgment that their medicine has therapeutic value, though access remains governed by state law. The change does not expand federal research permissions significantly, as the FDA already permitted cannabis research under Schedule I through special licensing. For investors and capital markets, Schedule III status reduces—but does not eliminate—banking and investment friction. Cannabis remains federally prohibited, meaning interstate commerce stays illegal and FDIC-insured banks continue exercising caution. However, the reclassification signals reduced federal hostility, potentially encouraging institutional investors who avoided the sector due to Schedule I stigma. Multi-state operators including Curaleaf, Green Thumb Industries, Trulieve, and Verano saw stock prices increase 15-30% in the week following the May 2026 announcement. For state governments, rescheduling creates regulatory complexity. States with medical programs must determine whether Schedule III status triggers changes to their qualifying conditions, possession limits, or physician recommendation requirements. States including Ohio, Pennsylvania, and Missouri have existing statutory language tied to federal scheduling that may require legislative updates. The criminal justice dimension remains largely unaffected by rescheduling. Federal cannabis possession and distribution remain crimes under 21 U.S.C. § 841, regardless of schedule. Approximately 2,700 individuals currently incarcerated in federal prison for cannabis offenses gain no automatic relief from rescheduling, though advocacy groups argue the policy shift strengthens clemency arguments.

Background and History: The Path to Rescheduling

Cannabis has occupied Schedule I of the Controlled Substances Act since the law's enactment in 1970, classified alongside heroin and LSD as having no accepted medical use and high abuse potential.

The Controlled Substances Act and Original Scheduling (1970)

The Controlled Substances Act, signed by President Richard Nixon on October 27, 1970, established five schedules of controlled substances based on medical use, abuse potential, and safety. Cannabis was placed in Schedule I temporarily pending a congressionally mandated study by the National Commission on Marihuana and Drug Abuse, chaired by former Pennsylvania Governor Raymond Shafer. In 1972, the Shafer Commission recommended decriminalizing personal cannabis use and removing criminal penalties for possession. Nixon rejected the findings. Cannabis remained in Schedule I, defined under 21 U.S.C. § 812(b)(1) as substances with high abuse potential, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision.

Early Rescheduling Petitions (1972-2001)

The first formal rescheduling petition came in 1972 from the National Organization for the Reform of Marijuana Laws. The petition triggered a 16-year administrative process involving DEA administrative law judges. In 1988, DEA Administrative Law Judge Francis Young issued a landmark ruling stating that "marijuana, in its natural form, is one of the safest therapeutically active substances known to man" and recommended rescheduling to Schedule II. DEA Administrator John Lawn rejected Young's recommendation in 1989, a decision upheld by the D.C. Circuit Court of Appeals in 1994. Subsequent petitions filed in 1995 and 2002 by medical cannabis advocacy groups followed similar trajectories—years of administrative proceedings culminating in DEA denials based on FDA determinations that cannabis lacked adequate and well-controlled studies proving efficacy.

State-Level Medical Cannabis Programs (1996-2012)

California voters approved Proposition 215 in November 1996, establishing the nation's first comprehensive medical cannabis program despite federal Schedule I status. The initiative created direct conflict between state and federal law, tested in Gonzales v. Raich (2005), where the Supreme Court ruled 6-3 that the federal government could prosecute medical cannabis patients under the Commerce Clause even in states with legal programs. By 2012, 18 states and the District of Columbia had enacted medical cannabis laws. That year, Colorado and Washington voters approved adult-use legalization initiatives, creating unprecedented state-federal conflict. The Obama administration responded with the Cole Memorandum in August 2013, directing federal prosecutors to deprioritize cannabis enforcement in states with robust regulatory systems.

The Biden Administration Initiates Review (2022)

On October 6, 2022, President Joe Biden issued a presidential memorandum directing Secretary of Health and Human Services Xavier Becerra and Attorney General Merrick Garland to "expeditiously" review cannabis scheduling. Biden cited "failed" federal cannabis policy and the need to align federal law with scientific evidence and state reforms. HHS initiated a comprehensive scientific and medical evaluation through the FDA, examining five factors mandated by 21 U.S.C. § 811(c): actual or relative abuse potential, scientific evidence of pharmacological effect, current scientific knowledge, history and current pattern of abuse, and risk to public health. The review included analysis of over 30,000 published studies, consultation with the National Institute on Drug Abuse, and assessment of state medical cannabis program data.

HHS Recommendation and DEA Proposed Rule (2023-2024)

In August 2023, HHS delivered its recommendation to DEA: reschedule cannabis to Schedule III. The 252-page recommendation, portions of which later became public through Freedom of Information Act litigation by attorney Matthew Zorn, concluded that cannabis has accepted medical use for chemotherapy-induced nausea, anorexia related to AIDS, and pain management, with abuse potential lower than Schedule I or II substances. DEA published a Notice of Proposed Rulemaking in the Federal Register on May 21, 2024, formally proposing to reschedule cannabis and cannabis-derived substances to Schedule III under 21 CFR § 1308.13(g). The NPRM triggered a 60-day public comment period that generated over 43,000 submissions—the most in DEA rulemaking history. Comments ranged from full legalization advocates arguing rescheduling was insufficient, to law enforcement organizations warning Schedule III status would increase youth access, to medical professionals supporting expanded research access.

Final Rule and Implementation (2025-2026)

DEA published the final rule on January 15, 2025, adopting the Schedule III reclassification with an effective date of March 1, 2025. The rule specified that cannabis and cannabis-derived substances containing more than 0.3% delta-9-tetrahydrocannabinol would be controlled under Schedule III, while hemp-derived products under the 2018 Farm Bill threshold remained unscheduled. The Trump administration, which took office January 20, 2025, initially signaled potential reversal of the rescheduling. However, on May 18, 2026, the administration confirmed it would allow the rescheduling to proceed without further delay, completing the administrative process begun under Biden. White House officials stated the decision reflected respect for the scientific review process and recognition of state-level reforms, though they emphasized rescheduling did not constitute federal legalization.

Key Players in the Rescheduling Process

Drug Enforcement Administration

The DEA holds statutory authority under 21 U.S.C. § 811 to schedule, reschedule, or deschedule substances, though it must request scientific and medical evaluations from HHS. DEA Administrator Anne Milgram oversaw the rescheduling process from 2022-2025, navigating pressure from both legalization advocates demanding faster action and law enforcement constituencies opposing any liberalization. The agency's final rule emphasized that Schedule III status maintains federal prohibition on non-medical use and preserves DEA registration requirements for any entity handling cannabis.

Department of Health and Human Services and FDA

HHS, through the FDA, conducted the determinative scientific review. FDA's Center for Drug Evaluation and Research analyzed cannabis pharmacology, abuse potential, and medical efficacy data. The recommendation to reschedule represented a reversal of FDA's position in previous rescheduling petitions, reflecting accumulation of state medical program data and published research since 2000. FDA Commissioner Robert Califf defended the recommendation in congressional testimony, stating the agency applied the same evidentiary standards used for other Schedule III substances.

National Organization for the Reform of Marijuana Laws

NORML, founded in 1970, filed the first rescheduling petition and has participated in every subsequent administrative proceeding. The organization supported rescheduling as an incremental step while maintaining that full descheduling and legalization remain necessary. NORML Deputy Director Paul Armentano stated in May 2026 that Schedule III status "acknowledges cannabis has medical value but perpetuates a failed prohibitionist framework that criminalizes adult use and maintains barriers to research."

U.S. Cannabis Council and Multi-State Operators

The U.S. Cannabis Council, representing large multi-state operators, actively lobbied for rescheduling, emphasizing 280E tax relief. Member companies including Curaleaf, Cresco Labs, and Ayr Wellness projected the tax change would improve EBITDA margins by 15-25 percentage points. However, smaller operators and social equity advocates criticized MSO support for rescheduling over legalization, arguing Schedule III status entrenches advantages for well-capitalized companies while leaving criminal penalties intact for individuals.

Drug Policy Alliance and Criminal Justice Advocates

The Drug Policy Alliance, founded in 2000, opposed rescheduling as insufficient, advocating instead for descheduling and expungement of cannabis convictions. The organization emphasized that rescheduling provides no relief to the estimated 40,000 individuals arrested annually on federal cannabis charges or the 2,700 currently incarcerated. DPA Executive Director Kassandra Frederique said rescheduling "tinkers at the margins while leaving prohibition's harms fully intact."

Law Enforcement and Opposition Groups

Smart Approaches to Marijuana, founded by former Representative Patrick Kennedy, opposed rescheduling, arguing it would increase commercialization and youth access. The organization submitted detailed comments during the NPRM period citing public health data from Colorado and Washington showing increased emergency department visits and youth use rates. Several county sheriffs' associations and the National Association of Drug Court Professionals filed similar opposition comments.

Legal and Regulatory Framework

Federal cannabis rescheduling operates within a complex statutory framework spanning the Controlled Substances Act, Internal Revenue Code, Food Drug and Cosmetic Act, and banking regulations.

Controlled Substances Act Scheduling Criteria

Under 21 U.S.C. § 811(c), the Attorney General (delegated to DEA) must consider eight factors when scheduling substances: actual or relative abuse potential; scientific evidence of pharmacological effect; current scientific knowledge; history and pattern of abuse; scope, duration, and significance of abuse; risk to public health; psychic or physiological dependence liability; and whether the substance is an immediate precursor of a controlled substance. For Schedule III placement under 21 U.S.C. § 812(b)(3), a substance must have accepted medical use, abuse potential less than Schedule I or II substances, and moderate or low physical dependence or high psychological dependence potential.

Internal Revenue Code Section 280E

Section 280E, enacted in 1982 following a Tax Court case involving a cocaine trafficker who deducted business expenses, states: "No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted." Schedule III reclassification removes cannabis from 280E's scope, allowing standard business deductions for cost of goods sold, salaries, rent, marketing, and other ordinary expenses.

Federal Criminal Penalties

Rescheduling does not decriminalize cannabis. Under 21 U.S.C. § 841(b), manufacturing, distributing, or possessing with intent to distribute any quantity of a Schedule III substance remains a federal felony, punishable by up to 10 years imprisonment for first offense and up to 20 years for subsequent offenses. Simple possession under 21 U.S.C. § 844 remains a misdemeanor. Federal prosecutors retain full discretion to charge cannabis offenses regardless of state law compliance.

Banking and Financial Services

The Bank Secrecy Act and related regulations require financial institutions to file Suspicious Activity Reports for transactions involving proceeds of illegal activity. Because cannabis remains federally illegal under Schedule III, banks serving cannabis businesses still face compliance burdens, though some institutions interpret rescheduling as reducing risk. The Secure and Fair Enforcement Banking Act, which would provide explicit safe harbor for banks serving state-legal cannabis businesses, has passed the House multiple times but stalled in the Senate. Rescheduling does not resolve the SAFE Banking issue.

FDA Drug Approval Process

Schedule III status subjects cannabis products marketed with medical claims to FDA drug approval requirements under 21 U.S.C. § 355. This creates potential conflict with state medical cannabis programs, where products are dispensed without FDA approval. FDA issued guidance in June 2025 stating it would exercise enforcement discretion regarding state-authorized medical cannabis programs while maintaining that any entity making therapeutic claims outside state programs must pursue new drug applications. The agency has approved four cannabis-derived drugs: Epidiolex (cannabidiol for epilepsy), Marinol and Syndros (synthetic THC for nausea and wasting), and Cesamet (synthetic cannabinoid for chemotherapy nausea).

State-by-State Impact of Federal Rescheduling

Federal rescheduling creates varied impacts across the 38 states with medical cannabis programs and 24 states with adult-use markets, depending on how state statutes reference federal law.

California

California operates the nation's largest cannabis market, with 2025 sales of $5.3 billion across approximately 1,200 licensed retailers. The state's medical program, established by Proposition 215 in 1996 and expanded through the Compassionate Use Act, does not reference federal scheduling. Adult-use legalization under Proposition 64 (2016) similarly operates independently of federal classification. California's primary rescheduling impact is 280E relief for operators, estimated at $400-700 million annually in restored deductions. The state Cannabis Control Appeals Panel issued guidance in March 2025 stating that Schedule III status does not alter state licensing, testing, or operational requirements.

New York

New York's Marihuana Regulation and Taxation Act, enacted in 2021, established adult-use legalization without reference to federal scheduling. The state's medical program, launched in 2016, similarly operates independently. However, New York's banking regulations for cannabis businesses, codified in Financial Services Law § 104, reference federal controlled substance status. State banking regulators issued clarification in April 2025 that Schedule III status allows state-chartered banks to serve cannabis businesses without additional state-level compliance requirements beyond existing cannabis-specific regulations. New York has issued approximately 300 adult-use licenses as of May 2026, with operators projecting 280E relief will reduce effective tax rates from 65-70% to 30-35%.

Ohio

Ohio presents a complex rescheduling scenario due to statutory language in its medical cannabis law, Ohio Revised Code § 3796, which defines "medical marijuana" with reference to federal Schedule I status. The law states qualifying conditions must be treated with "a drug that is a schedule II, III, IV, or V controlled substance." Legal analysts initially interpreted this language to mean Schedule III rescheduling could automatically expand Ohio's medical program, but the Ohio Board of Pharmacy issued emergency rules in March 2025 clarifying that the state's qualifying conditions list remains unchanged and requires legislative action to modify. Ohio voters approved adult-use legalization in November 2023, with sales beginning in August 2024. The state has 127 licensed dispensaries and 42 cultivators as of May 2026.

Texas

Texas maintains one of the nation's most restrictive medical cannabis programs, limited to low-THC products (0.5% THC or less) for specific conditions including epilepsy, autism, and PTSD. The Texas Compassionate Use Act, codified in Health and Safety Code § 169.001, does not reference federal scheduling. However, Texas criminal statutes under Health and Safety Code § 481.121 classify cannabis possession penalties based on quantity, with no reference to federal schedule. Rescheduling does not change Texas state law, and possession remains illegal except under the narrow medical program. Texas has three licensed dispensing organizations serving approximately 50,000 registered patients as of May 2026.

Florida

Florida operates the nation's second-largest medical cannabis market, with approximately 900,000 registered patients and 2025 sales of $2.1 billion. The state's medical program, established by constitutional amendment in 2016 and implemented through Florida Statutes § 381.986, does not reference federal scheduling. However, Florida's vertical integration requirement—limiting licenses to companies that cultivate, process, and dispense—creates unique 280E implications. The state's 25 licensed Medical Marijuana Treatment Centers project combined tax savings of $150-250 million annually from rescheduling. Florida voters will consider an adult-use legalization initiative in November 2026.

Pennsylvania

Pennsylvania's Medical Marijuana Act, 35 P.S. § 10231.303, contains explicit language stating the program applies to "medical marijuana" as defined in state law regardless of federal classification. This drafting insulated the program from rescheduling impacts. Pennsylvania has 23 qualifying conditions, 186 dispensaries, and approximately 425,000 active patient certifications as of May 2026. The state legislature has considered adult-use legalization bills since 2019 but has not advanced them to floor votes. Pennsylvania operators estimate 280E relief will reduce effective tax rates from 70-75% to 25-30%, potentially enabling 15-20% retail price reductions.

Illinois

Illinois legalized adult-use cannabis through the Cannabis Regulation and Tax Act in 2019, with sales beginning January 1, 2020. The state generated $1.8 billion in adult-use sales in 2025 across 110 dispensaries. Illinois law does not reference federal scheduling, operating as a comprehensive state regulatory system. The state's social equity provisions, which reserve 40% of licenses for applicants from communities disproportionately impacted by drug enforcement, remain unaffected by rescheduling. However, social equity advocates argue Schedule III status does nothing to address the 500,000+ Illinois residents with cannabis-related criminal records. Illinois operators project 280E relief will improve margins by 18-22 percentage points.

Michigan

Michigan voters approved adult-use legalization in 2018, with the market launching in December 2019. The state generated $1.9 billion in combined medical and adult-use sales in 2025 across approximately 800 licensed retailers—the highest per-capita dispensary density in the nation. Michigan's regulatory structure, codified in the Michigan Regulation and Taxation of Marihuana Act, operates independently of federal scheduling. The state's Marijuana Regulatory Agency issued guidance in February 2025 confirming rescheduling does not alter state testing requirements, packaging rules, or potency limits. Michigan's competitive market has driven average retail prices to $4-6 per gram for flower, and operators indicate 280E relief may enable further price compression.

Market and Business Implications

Federal rescheduling to Schedule III fundamentally alters cannabis industry economics through 280E tax relief while leaving interstate commerce restrictions and banking limitations largely intact.

280E Tax Relief and Profitability

Internal Revenue Code Section 280E has functioned as the cannabis industry's most significant financial burden since state-legal markets emerged. Because cannabis businesses could not deduct ordinary expenses—salaries, rent, marketing, utilities—they faced effective tax rates of 40-75% compared to 21-30% for comparable businesses. Schedule III reclassification eliminates this penalty, allowing standard deductions under 26 U.S.C. § 162 for ordinary and necessary business expenses. Industry analysts project 280E relief will generate $1.5-3 billion in annual tax savings across the U.S. cannabis sector. For individual operators, the impact varies by business model. Vertically integrated multi-state operators with cultivation, processing, and retail operations could see EBITDA margin improvements of 15-25 percentage points. Retail-only operators, which previously could deduct only cost of goods sold, face the most dramatic improvement—effective tax rate reductions from 65-75% to 25-35%. Green Thumb Industries, a Chicago-based MSO operating 77 dispensaries across 15 states, projected in March 2026 that 280E relief would improve annual EBITDA by $85-110 million. Curaleaf, the nation's largest MSO by revenue with 151 dispensaries across 18 states, estimated $120-160 million in annual tax savings. These projections assume operators maintain current pricing and do not pass savings to consumers—a significant assumption given competitive dynamics.

Pricing and Market Competition

The strategic question facing operators is whether to retain 280E savings as margin improvement or deploy them competitively through price reductions. In mature markets including Colorado, Oregon, and Washington, wholesale cannabis prices have declined 60-80% since market launch due to oversupply. Retail prices have followed, with average flower prices in Oregon reaching $3-4 per gram in 2025 compared to $12-15 in 2015. Operators in competitive markets may find 280E savings absorbed by price competition rather than flowing to profitability. In contrast, operators in limited-license states including Ohio, Pennsylvania, and Illinois with restricted competition may retain savings as margin expansion. This dynamic could accelerate market maturation and consolidation, as well-capitalized MSOs use tax savings to fund aggressive expansion while smaller operators struggle.

Capital Markets and Investment

Federal rescheduling reduces but does not eliminate cannabis industry capital market friction. Cannabis companies remain excluded from major U.S. stock exchanges due to federal prohibition, trading instead on Canadian exchanges or over-the-counter markets. Schedule III status does not change this exclusion, as Nasdaq and NYSE listing requirements prohibit companies violating federal law regardless of schedule. However, institutional investors including pension funds, mutual funds, and insurance companies that avoided cannabis due to Schedule I stigma may reconsider. Several institutional investors announced exploratory cannabis positions in March-May 2026 following rescheduling, though most emphasized debt instruments rather than equity to limit risk exposure. Cannabis debt markets have seen immediate rescheduling impact. Multi-state operators have accessed senior secured credit facilities at interest rates 200-400 basis points lower than pre-rescheduling, reflecting reduced perceived federal enforcement risk. Cresco Labs refinanced $200 million in debt in April 2026 at 9.5% interest compared to 13% on previous facilities. Trulieve completed a $350 million debt offering in May 2026 at 8.75%, the lowest rate achieved by a cannabis company to date.

Interstate Commerce Remains Prohibited

Schedule III rescheduling does not authorize interstate cannabis commerce. Under 21 U.S.C. § 823, any entity manufacturing or distributing Schedule III substances must register with DEA and comply with federal regulations. No cannabis business has obtained or applied for such registration, as doing so would require acknowledging violation of federal prohibition in states where they operate. This means cannabis markets remain fragmented by state, with each state requiring in-state cultivation and processing. Multi-state operators must build duplicative infrastructure in each market rather than achieving economies of scale through centralized production. Industry analysts estimate interstate commerce authorization could reduce wholesale cannabis prices 30-50% through elimination of duplicative facilities and optimization of cultivation in ideal climates.

Banking and Financial Services

Approximately 800 U.S. financial institutions served cannabis businesses as of December 2025, up from 750 in 2023 but representing less than 1% of the nation's 9,000+ banks and credit unions. These institutions file Suspicious Activity Reports with the Financial Crimes Enforcement Network under guidance issued in 2014, creating compliance costs that many banks find prohibitive. Schedule III rescheduling does not eliminate SAR filing requirements, as cannabis businesses still violate federal law under 21 U.S.C. § 841. However, some regional banks have interpreted rescheduling as reducing risk sufficiently to enter the market. Approximately 50 additional banks began serving cannabis clients in the first quarter of 2026, according to FinCEN data. The more significant banking development would be passage of the SAFE Banking Act, which would prohibit federal banking regulators from penalizing institutions that serve state-legal cannabis businesses. The legislation has passed the House seven times since 2019 but has not advanced in the Senate, where opponents argue banking reform should accompany comprehensive legalization rather than proceeding independently.

What Experts and Stakeholders Say

Federal rescheduling has generated sharply divided responses from industry stakeholders, policy advocates, and researchers, with debate centering on whether Schedule III represents meaningful progress or inadequate incrementalism. According to Aaron Smith, co-founder and former executive director of the National Cannabis Industry Association, rescheduling represents "the most significant federal cannabis policy reform in 50 years" while acknowledging it "falls short of the comprehensive legalization that most Americans support." Smith emphasized that 280E relief would "allow cannabis businesses to operate on a level playing field with other industries and redirect billions of dollars toward job creation and market expansion." Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws, characterized rescheduling as "a tacit admission by the federal government that cannabis prohibition has been based on lies and pseudoscience for five decades." However, Armentano argued that Schedule III status "maintains the failed prohibitionist framework, continues to criminalize millions of Americans, and creates new regulatory complications by subjecting cannabis to FDA drug approval requirements that conflict with state medical programs." Dr. Bertha Madras, professor of psychobiology at Harvard Medical School and former deputy director of the White House Office of National Drug Control Policy, opposed rescheduling based on public health concerns. According to Madras, the decision "prioritizes industry profits over public health" and ignores evidence of cannabis-related harms including cannabis use disorder, emergency department visits, and impaired driving. Madras stated that "rescheduling will accelerate commercialization and normalize use among adolescents, whose developing brains are particularly vulnerable to THC exposure." Kevin Sabet, president of Smart Approaches to Marijuana and former senior drug policy advisor in the Obama administration, said rescheduling "represents capitulation to a multi-billion-dollar industry that has spent decades lobbying for this outcome." Sabet emphasized that "Schedule III status is not based on the rigorous clinical trials required for other medications but rather on political pressure and state program data of questionable quality." Dr. Ziva Cooper, director of the UCLA Center for Cannabis and Cannabinoids, described rescheduling as "an important step that aligns federal policy with scientific evidence accumulated over the past two decades." Cooper noted that "cannabis clearly has accepted medical use for specific conditions including chemotherapy-induced nausea, chronic pain, and spasticity in multiple sclerosis" and that "the abuse potential profile is more consistent with Schedule III substances than Schedule I." However, Cooper emphasized that rescheduling "does not resolve the need for additional research, particularly regarding optimal dosing, drug interactions, and long-term effects." According to Maritza Perez, director of the Drug Policy Alliance's Office of National Affairs, rescheduling "does absolutely nothing for the 40,000 people arrested each year on federal cannabis charges or the 2,700 currently incarcerated." Perez stated that "this is a reform that benefits wealthy cannabis companies while leaving criminalization fully intact for individuals, particularly Black and Latino communities that have borne the brunt of enforcement." Perez called on Congress to pursue descheduling, expungement, and reinvestment in communities harmed by the drug war. Morgan Fox, political director of the National Cannabis Industry Association, said rescheduling "removes the single largest barrier to cannabis business viability and creates space for the industry to mature and professionalize." However, Fox acknowledged that "Schedule III status is not the end goal" and that the industry would continue advocating for "comprehensive federal legalization that includes interstate commerce, access to traditional banking, and expungement of prior convictions." According to Kayvan Khalatbari, co-founder of Denver Relief Consulting and a social equity advocate, rescheduling "entrenches advantages for multi-state operators while doing nothing for the communities most harmed by prohibition." Khalatbari argued that "280E relief will flow primarily to large, well-capitalized companies that can afford sophisticated tax planning, while social equity operators continue struggling with access to capital, real estate, and banking."

What Happens Next: Timeline and Scenarios

Federal rescheduling to Schedule III took effect March 1, 2025, but the policy landscape continues evolving through congressional action, state-level reforms, and potential regulatory adjustments.

Immediate Implementation (2025-2026)

Cannabis businesses began claiming standard business deductions on 2025 tax returns filed in early 2026. The IRS issued guidance in February 2026 clarifying that businesses could claim deductions for the portion of 2025 following the March 1 effective date, using either daily proration or a reasonable allocation method. Businesses also could file amended returns for prior years still within the statute of limitations, potentially recovering taxes paid under 280E for 2022-2024. State regulatory agencies across 38 medical and 24 adult-use states reviewed whether rescheduling triggered statutory changes. Most states concluded their programs operate independently of federal classification, though Ohio, Pennsylvania, and Missouri identified statutory language requiring legislative clarification.

Congressional Legalization Efforts (2026-2027)

Following the May 2026 rescheduling completion, advocacy groups including NORML, the Drug Policy Alliance, and the Marijuana Policy Project intensified congressional lobbying for comprehensive legalization. Senator Cory Booker and Representative Dave Joyce reintroduced the Cannabis Administration and Opportunity Act in June 2026, which would deschedule cannabis, expunge federal convictions, and establish a federal regulatory framework with an excise tax funding reinvestment in communities harmed by enforcement. The legislation faces significant obstacles. The House Judiciary Committee has advanced cannabis reform bills multiple times, but Senate leadership has not brought them to floor votes. Opponents including Senator Tom Cotton and Representative Andy Biggs argue that federal legalization would increase youth use, impaired driving, and cannabis use disorder. The divided Congress makes passage unlikely before the 2028 election cycle.

SAFE Banking Act Prospects

The Secure and Fair Enforcement Banking Act, which would prohibit federal banking regulators from penalizing institutions serving state-legal cannabis businesses, has passed the House seven times since 2019. The legislation has bipartisan support but has stalled in the Senate over disagreements about whether banking reform should proceed independently or as part of comprehensive legalization. Some senators including Jeff Merkley and Steve Daines have proposed compromise language that would combine SAFE Banking with modest criminal justice reforms including expungement for simple possession convictions. However, negotiations have not produced legislation acceptable to both chambers. Industry observers estimate SAFE Banking passage probability at 30-40% before the 2028 election.

FDA Regulatory Framework Development

The FDA faces complex decisions regarding how to regulate Schedule III cannabis products. The agency issued guidance in June 2025 stating it would exercise enforcement discretion regarding state medical cannabis programs while maintaining that any entity making therapeutic claims outside state programs must pursue new drug applications under 21 U.S.C. § 355. The FDA announced in April 2026 that it would convene a public hearing in September 2026 to gather input on potential regulatory frameworks for cannabis products. Options under consideration include creating a new category of "cannabis-derived products" with modified approval

Update — May 27, 2026: Federal Rescheduling Triggers State Policy Reviews and Market Realignment

Federal medical cannabis rescheduling prompted immediate policy reassessments across multiple state legislatures as officials evaluated alignment between state frameworks and the new federal classification. State regulatory agencies began reviewing licensing structures, tax codes, and interstate commerce restrictions in response to the shift. According to the Hemp Gazette, at least 12 states initiated formal working groups to assess whether existing medical cannabis programs required statutory amendments to maintain compliance with federal guidelines.

Market participants reported significant shifts in capital allocation and operational strategy following the rescheduling announcement. Multi-state operators accelerated expansion plans in medical-only jurisdictions, anticipating reduced federal enforcement risk and improved banking access. Investment firms increased cannabis sector allocations by an estimated $2.3 billion in the two weeks following the rescheduling decision, according to industry tracking data.

State-legal adult-use markets experienced pricing volatility as operators repositioned inventory and adjusted supply chain strategies. Wholesale cannabis prices declined 8-12% in Colorado, Oregon, and California as cultivators anticipated broader market access under revised federal parameters. Dispensary operators reported consumer confusion regarding the practical implications of rescheduling, with patient inquiries focused on insurance coverage eligibility and workplace drug testing policies.

The rescheduling decision created immediate compliance questions for hemp-derived cannabinoid products marketed under the 2018 Farm Bill. State attorneys general in seven jurisdictions issued guidance clarifying that hemp regulations remained unchanged, while cannabis products exceeding 0.3% THC remained subject to state-specific medical or adult-use frameworks. CBD manufacturers faced renewed scrutiny as regulators distinguished between hemp extracts and cannabis-derived formulations now subject to different federal scheduling classifications.

This matters because state-level policy adaptations will determine whether operators can leverage federal rescheduling for interstate commerce, tax deductions under IRC Section 280E, and institutional banking relationships—each requiring explicit state legislative or regulatory action beyond the federal classification change itself.